Goldman Sachs
AVDL

Goldman Sachs’s Avadel Pharmaceuticals AVDL Stock Holding History

Goldman Sachs’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-250,000
Closed -$1.99M – 5191
2020
Q1 		$1.99M Buy
+250,000
New +$1.92M ﹤0.01% 3303

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's AVDL Position: Q1 2026 in Review

Goldman Sachs sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 655,058 shares — an estimated $14.1M sold.

Goldman Sachs first reported a position in AVDL in Q1 2016 and held it in 34 quarters. The position peaked at $24.4M in Q3 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Goldman Sachs reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 655,058 Avadel Pharmaceuticals shares in Q1 2026, an estimated $14.1M.
  • Goldman Sachs first reported a position in Avadel Pharmaceuticals in Q1 2016 and held it in 34 quarters.
  • Goldman Sachs's Avadel Pharmaceuticals position peaked at $24.4M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.